(Q40434933)

2 July 2019

title

Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia (English)

1 reference

2 July 2019

13

Tanios Bekaii-Saab

0 references

Guido Marcucci

11

object named as

Guido Marcucci

1 reference

2 July 2019

Yu-Chou Tseng

1

1 reference

2 July 2019

Samuel K Kulp

2

1 reference

2 July 2019

I-Lu Lai

3

1 reference

2 July 2019

En-Chi Hsu

4

1 reference

2 July 2019

Wei A He

5

1 reference

2 July 2019

David E Frankhouser

6

1 reference

2 July 2019

Pearlly S Yan

7

1 reference

2 July 2019

Xiaokui Mo

8

1 reference

2 July 2019

Mark Bloomston

9

1 reference

2 July 2019

Gregory B Lesinski

10

1 reference

2 July 2019

Denis C Guttridge

12

1 reference

2 July 2019

Ching-Shih Chen

14

1 reference

2 July 2019

language of work or name

English

0 references

publication date

12 October 2015

1 reference

2 July 2019

Journal of the National Cancer Institute

published in

1 reference

2 July 2019

volume

107

1 reference

2 July 2019

issue

12

1 reference

2 July 2019

page(s)

djv274

1 reference

2 July 2019

Cachexia as a major underestimated and unmet medical need: facts and numbers

cites work

1 reference

12 December 2020

Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control

1 reference

12 December 2020

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma

1 reference

12 December 2020

Treating cancer cachexia to treat cancer

1 reference

12 December 2020

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

1 reference

12 December 2020

The role of insulin resistance in the development of muscle wasting during cancer cachexia

1 reference

12 December 2020

Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia

1 reference

12 December 2020

Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia

1 reference

12 December 2020

Biochemistry and pathophysiology of intravascular and intracellular lipolysis

1 reference

12 December 2020

Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption

1 reference

12 December 2020

OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model

1 reference

12 December 2020

Cellular and molecular mechanisms of muscle atrophy

1 reference

12 December 2020

Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models

1 reference

12 December 2020

The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo

1 reference

12 December 2020

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

1 reference

12 December 2020

Mechanisms of cancer cachexia

1 reference

12 December 2020

Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice

1 reference

12 December 2020

Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.

1 reference

12 December 2020

Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins

1 reference

12 December 2020

p300 Acetyltransferase activity differentially regulates the localization and activity of the FOXO homologues in skeletal muscle.

1 reference

12 December 2020

Cancer cachexia: mediators, signaling, and metabolic pathways

1 reference

12 December 2020

Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.

1 reference

12 December 2020

Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting

1 reference

12 December 2020

Histone deacetylase inhibitors in cancer therapy

1 reference

12 December 2020

The role of triglyceride lipases in cancer associated cachexia.

1 reference

12 December 2020

Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy

1 reference

12 December 2020

Identification of ubiquitin ligases required for skeletal muscle atrophy

1 reference

12 December 2020

Cancer cachexia is regulated by selective targeting of skeletal muscle gene products

1 reference

12 December 2020

The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia.

1 reference

12 December 2020

Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression

1 reference

12 December 2020

alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population

1 reference

12 December 2020

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer

1 reference

12 December 2020

Current pharmacotherapy options for cancer anorexia and cachexia

1 reference

12 December 2020

A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer

1 reference

12 December 2020

Acetylation and deacetylation--novel factors in muscle wasting

1 reference

12 December 2020

Oxidative stress, chronic disease, and muscle wasting

1 reference

12 December 2020

Evidence for the involvement of interleukin 6 in experimental cancer cachexia

1 reference

12 December 2020

Atrogin-1, MuRF-1, and sarcopenia

1 reference

12 December 2020

1 reference

12 December 2020

Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans

1 reference

12 December 2020

Cachexia in cancer patients

1 reference

12 December 2020

Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy

1 reference

12 December 2020

HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy

1 reference

12 December 2020

Learning to predict cancer-associated skeletal muscle wasting from 1H-NMR profiles of urinary metabolites

1 reference

5 May 2024

https://opencitations.net/index/api/v1/citations/10.1007/S11306-010-0232-9

Identifiers

DOI

10.1093/JNCI/DJV274

1 reference

2 July 2019

PMC publication ID

6280990

1 reference

2 July 2019

PubMed publication ID

26464423

1 reference

2 July 2019